You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • Reference number: TA193
  • Published:  28 July 2010
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Leukaemia (chronic lymphocytic, relapsed) - rituximab: expert comments on the ACD

  • Leukaemia (chronic lymphocytic, relapsed) - rituximab: expert comments on the ACD - Williams

  • Leukaemia (chronic lymphocytic, relapsed) - rituximab: expert comments on the ACD - Barnard


This page was last updated: 30 March 2010

Back to top